Cargando…
Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population
BACKGROUND: Significant anxiety symptoms are associated with poor clinical course and outcome in major depressive disorder (MDD). This single-arm, open-label study aimed to evaluate the efficacy and tolerability of escitalopram treatment in patients with MDD and anxiety symptoms. METHODS: Adult pati...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5322850/ https://www.ncbi.nlm.nih.gov/pubmed/28255239 http://dx.doi.org/10.2147/NDT.S120190 |
_version_ | 1782509924846141440 |
---|---|
author | Jiang, Kaida Li, Lingjiang Wang, Xueyi Fang, Maosheng Shi, Jianfei Cao, Qiuyun He, Jincai Wang, Jinan Tan, Weihao Hu, Cuili |
author_facet | Jiang, Kaida Li, Lingjiang Wang, Xueyi Fang, Maosheng Shi, Jianfei Cao, Qiuyun He, Jincai Wang, Jinan Tan, Weihao Hu, Cuili |
author_sort | Jiang, Kaida |
collection | PubMed |
description | BACKGROUND: Significant anxiety symptoms are associated with poor clinical course and outcome in major depressive disorder (MDD). This single-arm, open-label study aimed to evaluate the efficacy and tolerability of escitalopram treatment in patients with MDD and anxiety symptoms. METHODS: Adult patients with MDD and anxiety symptoms (Montgomery–Asberg Depression Rating Scale [MADRS] ≥22 and Hamilton Anxiety Rating Scale [HAM-A] ≥14) were enrolled and received escitalopram (10–20 mg/day) treatment for 24 weeks. Symptom status was assessed by MADRS, 17-item-Hamilton Depression Rating Scale, HAM-A, and Clinical Global Impression Scale at baseline and the following visits. Quality of life was assessed by Short Form-12, and safety was evaluated by adverse events, laboratory investigations, vital signs, and physical findings. RESULTS: Overall, 200 of 318 (66.2%) enrolled patients completed the 24-week treatment. The remission (MADRS ≤10 and HAM-A ≤7) rate in the full analysis set (N=285) was 73.3% (95% confidence interval: 67.80, 78.38) at week 24. Mean (± standard deviation) MADRS total score was 33.4 (±7.13) and HAM-A score was 27.6 (±7.26) at baseline, which reduced to 6.6 (±10.18) and 6.0 (±8.39), respectively, at week 24. Patients with higher baseline depression and anxiety level took longer to achieve similar remission rates. Overall, 80 of the 302 (26.5%) patients included in the safety set reported at least 1 treatment-emergent adverse event (TEAE). Most frequently reported TEAEs (>2%) were headache (4.0%), nasopharyngitis (3.6%), nausea (3.0%), and dizziness (2.6%). Serious TEAEs were reported by 1.3% patients; no deaths were reported. CONCLUSION: Escitalopram 10–20 mg/day was effective and well-tolerated in the long-term treatment of MDD with anxiety symptoms in adult Chinese population. |
format | Online Article Text |
id | pubmed-5322850 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-53228502017-03-02 Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population Jiang, Kaida Li, Lingjiang Wang, Xueyi Fang, Maosheng Shi, Jianfei Cao, Qiuyun He, Jincai Wang, Jinan Tan, Weihao Hu, Cuili Neuropsychiatr Dis Treat Original Research BACKGROUND: Significant anxiety symptoms are associated with poor clinical course and outcome in major depressive disorder (MDD). This single-arm, open-label study aimed to evaluate the efficacy and tolerability of escitalopram treatment in patients with MDD and anxiety symptoms. METHODS: Adult patients with MDD and anxiety symptoms (Montgomery–Asberg Depression Rating Scale [MADRS] ≥22 and Hamilton Anxiety Rating Scale [HAM-A] ≥14) were enrolled and received escitalopram (10–20 mg/day) treatment for 24 weeks. Symptom status was assessed by MADRS, 17-item-Hamilton Depression Rating Scale, HAM-A, and Clinical Global Impression Scale at baseline and the following visits. Quality of life was assessed by Short Form-12, and safety was evaluated by adverse events, laboratory investigations, vital signs, and physical findings. RESULTS: Overall, 200 of 318 (66.2%) enrolled patients completed the 24-week treatment. The remission (MADRS ≤10 and HAM-A ≤7) rate in the full analysis set (N=285) was 73.3% (95% confidence interval: 67.80, 78.38) at week 24. Mean (± standard deviation) MADRS total score was 33.4 (±7.13) and HAM-A score was 27.6 (±7.26) at baseline, which reduced to 6.6 (±10.18) and 6.0 (±8.39), respectively, at week 24. Patients with higher baseline depression and anxiety level took longer to achieve similar remission rates. Overall, 80 of the 302 (26.5%) patients included in the safety set reported at least 1 treatment-emergent adverse event (TEAE). Most frequently reported TEAEs (>2%) were headache (4.0%), nasopharyngitis (3.6%), nausea (3.0%), and dizziness (2.6%). Serious TEAEs were reported by 1.3% patients; no deaths were reported. CONCLUSION: Escitalopram 10–20 mg/day was effective and well-tolerated in the long-term treatment of MDD with anxiety symptoms in adult Chinese population. Dove Medical Press 2017-02-17 /pmc/articles/PMC5322850/ /pubmed/28255239 http://dx.doi.org/10.2147/NDT.S120190 Text en © 2017 Jiang et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Jiang, Kaida Li, Lingjiang Wang, Xueyi Fang, Maosheng Shi, Jianfei Cao, Qiuyun He, Jincai Wang, Jinan Tan, Weihao Hu, Cuili Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population |
title | Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population |
title_full | Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population |
title_fullStr | Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population |
title_full_unstemmed | Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population |
title_short | Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population |
title_sort | efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in chinese population |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5322850/ https://www.ncbi.nlm.nih.gov/pubmed/28255239 http://dx.doi.org/10.2147/NDT.S120190 |
work_keys_str_mv | AT jiangkaida efficacyandtolerabilityofescitalopramintreatmentofmajordepressivedisorderwithanxietysymptomsa24weekopenlabelprospectivestudyinchinesepopulation AT lilingjiang efficacyandtolerabilityofescitalopramintreatmentofmajordepressivedisorderwithanxietysymptomsa24weekopenlabelprospectivestudyinchinesepopulation AT wangxueyi efficacyandtolerabilityofescitalopramintreatmentofmajordepressivedisorderwithanxietysymptomsa24weekopenlabelprospectivestudyinchinesepopulation AT fangmaosheng efficacyandtolerabilityofescitalopramintreatmentofmajordepressivedisorderwithanxietysymptomsa24weekopenlabelprospectivestudyinchinesepopulation AT shijianfei efficacyandtolerabilityofescitalopramintreatmentofmajordepressivedisorderwithanxietysymptomsa24weekopenlabelprospectivestudyinchinesepopulation AT caoqiuyun efficacyandtolerabilityofescitalopramintreatmentofmajordepressivedisorderwithanxietysymptomsa24weekopenlabelprospectivestudyinchinesepopulation AT hejincai efficacyandtolerabilityofescitalopramintreatmentofmajordepressivedisorderwithanxietysymptomsa24weekopenlabelprospectivestudyinchinesepopulation AT wangjinan efficacyandtolerabilityofescitalopramintreatmentofmajordepressivedisorderwithanxietysymptomsa24weekopenlabelprospectivestudyinchinesepopulation AT tanweihao efficacyandtolerabilityofescitalopramintreatmentofmajordepressivedisorderwithanxietysymptomsa24weekopenlabelprospectivestudyinchinesepopulation AT hucuili efficacyandtolerabilityofescitalopramintreatmentofmajordepressivedisorderwithanxietysymptomsa24weekopenlabelprospectivestudyinchinesepopulation |